BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Velosa J, Serejo F, Marinho R, Nunes J, Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci. 2011;56:1853-1861. [PMID: 21374066 DOI: 10.1007/s10620-011-1621-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Velosa J, Serejo F, Ramalho F, Marinho R, Rodrigues B, Baldaia C, Raimundo M, Ferreira P. A practical guide for antiviral therapy of chronic Hepatitis C. GE Portuguese Journal of Gastroenterology 2014;21:221-30. [DOI: 10.1016/j.jpge.2014.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Parise ER. 25 years of Hepatitis C. Arq Gastroenterol 2015;52:1-3. [DOI: 10.1590/s0004-28032015000100001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol 2018;31:670-9. [PMID: 30386116 DOI: 10.20524/aog.2018.0306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 Boursier J, Ducancelle A, Vergniol J, Veillon P, Moal V, Dufour C, Bronowicki JP, Larrey D, Hézode C, Zoulim F, Fontaine H, Canva V, Poynard T, Allam S, De Lédinghen V; ANRS CO20 CUPIC Study Group. The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients. J Viral Hepat 2015;22:1002-10. [PMID: 26216230 DOI: 10.1111/jvh.12433] [Reference Citation Analysis]
5 Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19. [PMID: 25596623 DOI: 10.1186/s12879-015-0748-8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 15.0] [Reference Citation Analysis]
6 Weiler N, Zeuzem S, Welker MW. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol 2016; 22(41): 9044-9056 [PMID: 27895394 DOI: 10.3748/wjg.v22.i41.9044] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Huang Y, Wei L, Zhao RC, Liang WB, Zhang J, Ding XQ, Li ZL, Sun CJ, Li B, Liu QY, He JY, Yu XQ, Gao B, Chen MM, Sun AM, Qin Y. Predicting hepatocellular carcinoma development for cirrhosis patients via methylation detection of heparocarcinogenesis-related genes. J Cancer 2018;9:2203-10. [PMID: 29937940 DOI: 10.7150/jca.24024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Toyota J. Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection. Ann Hepatol 2021;27:100566. [PMID: 34688887 DOI: 10.1016/j.aohep.2021.100566] [Reference Citation Analysis]
9 Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54:1259-1271. [PMID: 22412061 DOI: 10.1093/cid/cis011] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 7.5] [Reference Citation Analysis]
10 Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol 2017;17:46. [PMID: 28376711 DOI: 10.1186/s12876-017-0606-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
11 Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V, Craxì A, Di Marco V, Cammà C, Calvaruso V, Petta S, Cabbibbo G, Colletti P, Mazzola G, Cascio A, Montalto G, Licata A, Giannitrapani L, Prestileo T, Di Lorenzo F, Sanfilippo A, Ficalora A, Madonia S, Tinè F, Malizia G, Latteri F, Maida M, Cartabellotta F, Vassallo R, Cacciola I, Caccamo G, Maimone S, Saitta C, Squadrito G, Raimondo G, Mondello L, Smedile A, D’andrea S, Bertino G, Ardiri A, Frazzetto E, Rigano G, Montineri A, Larocca L, Cacopardo B, Benanti F, Russello M, Benigno R, Bellia A, Iacobello C, Davì A, Di Rosolini M, Digiacomo A, Fuduli G, Scifo G, Distefano M, Portelli V, Savalli F, Scalici I, Gioia G, Magro A, Alaimo G, Alinovi M, Salvo A, Averna A, Lomonaco F, Guarneri L, Maffeo F, Falzone E, Pulvirenti F. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 2018;155:411-421.e4. [DOI: 10.1053/j.gastro.2018.04.008] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 38.3] [Reference Citation Analysis]
12 Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwolleghem T, Verlinden W, Brixco C, Decaestecker J, de Galocsy C. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience. J Viral Hepat. 2017;24:976-981. [PMID: 28504854 DOI: 10.1111/jvh.12726] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
13 Macaluso FS, Calvaruso V, Craxì A. Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. Future Microbiol 2015;10:977-88. [PMID: 26059621 DOI: 10.2217/fmb.15.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
15 van Tilborg M, Maan R, van der Meer AJ, de Knegt RJ. Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. Best Pract Res Clin Gastroenterol 2017;31:219-25. [PMID: 28624110 DOI: 10.1016/j.bpg.2017.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Messori A, Badiani B, Trippoli S. Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures. Clin Drug Investig 2015;35:843-50. [DOI: 10.1007/s40261-015-0338-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
17 Li CF, Tsao SM, Liao HH, Chen SC, Lee YT. Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e22435. [PMID: 33019424 DOI: 10.1097/MD.0000000000022435] [Reference Citation Analysis]
18 Ampuero J, Campo JAD, Rojas L, García-lozano JR, Solá R, Andrade R, Pons JA, Navarro JM, Calleja JL, Buti M, González-escribano MF, Forns X, Diago M, García-samaniego J, Romero-gómez M. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. Annals of Hepatology 2014;13:356-63. [DOI: 10.1016/s1665-2681(19)30842-7] [Cited by in Crossref: 14] [Article Influence: 1.8] [Reference Citation Analysis]
19 Nakatsuka K, Atsukawa M, Shimizu M, Takahashi H, Kawamoto C. Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol 2015; 7(25): 2590-2596 [PMID: 26557951 DOI: 10.4254/wjh.v7.i25.2590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Carrión JA, Gonzalez-colominas E, García-retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-santos R, Solà R. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. Journal of Hepatology 2013;59:926-33. [DOI: 10.1016/j.jhep.2013.06.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
21 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
22 Tran HA, Jones TL, Ianna EA, Foy A, Reeves GE. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract 2013;19:292-300. [PMID: 23186968 DOI: 10.4158/EP12195.RA] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
23 Satoskar R, Reau N. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology 2013;58:422-7. [PMID: 23460345 DOI: 10.1002/hep.26349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67:1204-1212. [PMID: 28802876 DOI: 10.1016/j.jhep.2017.07.025] [Cited by in Crossref: 253] [Cited by in F6Publishing: 231] [Article Influence: 50.6] [Reference Citation Analysis]
25 Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, Clark V, Morelli G, Firpi R, Nelson DR. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37:91-7. [PMID: 23094860 DOI: 10.1111/apt.12098] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lee M, Yang H, Chen C. Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study. BioMedicine 2012;2:99-107. [DOI: 10.1016/j.biomed.2012.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Hasegawa T, Toyota J. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients. J Gastroenterol Hepatol 2021;36:367-75. [PMID: 32991760 DOI: 10.1111/jgh.15280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, Diels J, Lawson A, Neal KR, Wiselka MJ. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat. 2014;21:208-215. [PMID: 24438682 DOI: 10.1111/jvh.12132] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]